Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 675,000 ordinary shares of 25 pence each.
- Purchase Price: 1,518.617 pence per share.
- Treasury Shares Held: 155,864,678 shares following the transaction.
- Shares in Issue: 5,818,342,994 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on March 28, 2006. This action was taken under authority granted by shareholders at the Annual General Meeting on May 25, 2005. The purchased shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying the 675,000 shares by the 1,518.617 pence price.
- Confirm the impact of the 155,864,678 Treasury shares on the company's total share capital and earnings per share calculations.
- Review the May 25, 2005 Annual General Meeting minutes to understand the full scope of the share buyback authority granted.